BACKGROUND: The prognostic significance of mutant p53 protein, p-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) in patients with unresectable non-small cell lung cancer (NSCLC) has not been established. MATERIALS AND METHODS: We performed immunohistochemical staining of p53, P-gp and GST-pi using transbronchial biopsy specimens obtained from previously untreated NSCLC patients. RESULTS: Of 45 patients examined, p53 immunostaining was positive in 18 (40%) patients. The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Survival of the patients with p53-positive tumors was significantly shorter than those with p53-negative tumors (median survival time: 4.6 months versus 12.2 months, p = 0.011), which was confirmed by the multivariate analysis (p = 0.0243). However, P-gp and GST-pi showed no significant relationship with either response rate or survival in patients with unresectable NSCLC receiving CDDP-based chemotherapy. CONCLUSION: p53 alteration is an independent and significant indicator to predict unfavorable prognosis in patients with unresectable NSCLC.
BACKGROUND: The prognostic significance of mutant p53 protein, p-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) in patients with unresectable non-small cell lung cancer (NSCLC) has not been established. MATERIALS AND METHODS: We performed immunohistochemical staining of p53, P-gp and GST-pi using transbronchial biopsy specimens obtained from previously untreated NSCLCpatients. RESULTS: Of 45 patients examined, p53 immunostaining was positive in 18 (40%) patients. The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Survival of the patients with p53-positive tumors was significantly shorter than those with p53-negative tumors (median survival time: 4.6 months versus 12.2 months, p = 0.011), which was confirmed by the multivariate analysis (p = 0.0243). However, P-gp and GST-pi showed no significant relationship with either response rate or survival in patients with unresectable NSCLC receiving CDDP-based chemotherapy. CONCLUSION:p53 alteration is an independent and significant indicator to predict unfavorable prognosis in patients with unresectable NSCLC.
Authors: Eric S Kim; J Jack Lee; Guangan He; Chi-Wan Chow; Junya Fujimoto; Neda Kalhor; Stephen G Swisher; Ignacio I Wistuba; David J Stewart; Zahid H Siddik Journal: J Clin Oncol Date: 2012-08-13 Impact factor: 44.544
Authors: Catherine A Vaughan; Shilpa Singh; Brad Windle; W Andrew Yeudall; Rebecca Frum; Steven R Grossman; Swati P Deb; Sumitra Deb Journal: Genes Cancer Date: 2012-07